Proteinase 3 (PR3) Chimeric Autoantibody Receptor T Cells and Related Methods and Uses

JP2025508783A5Pending Publication Date: 2026-03-03JUNO THERAPEUTICS INC
0 Cites 0 Cited by

Patent Information

Application Number
JP2024549484
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-02-22
Filing Date
2023-02-21
Publication Date
2026-03-03

AI Technical Summary

Technical Problem

Current methods are inadequate for effectively targeting and eliminating disease-causing B cells in antineutrophil cytoplasmic antibody-associated vasculitis (AAV) by activating primed neutrophils that damage blood vessels.

Method used

Development of chimeric autoantibody receptors (CAARs) that include an extracellular proteinase 3 (PR3) antibody binding domain, a transmembrane region, and an intracellular signaling region, which are capable of specific binding to anti-PR3 antineutrophil cytoplasmic antibodies (ANCAs) and inducing targeted killing of PR3-reactive B cells.

Benefits of technology

The CAARs demonstrate the ability to specifically target and kill PR3-reactive B cells, offering a potential therapeutic approach for AAV by reducing the autoimmune response and associated vascular damage.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided herein are cell and protein therapeutics comprising proteinase 3 (PR3) antibody binding domain, for example, wild-type PR3 protein or mutant PR3 protein, and methods of using the same.Also provided herein are chimeric autoantibody receptors (CAARs) comprising extracellular PR3 antibody binding domains.Among the CAARs provided are CAARs whose extracellular PR3 antibody binding domains are wild-type or mutant PR3 proteins or fragments thereof that can receive specific binding of anti-PR3 antineutrophil cytoplasmic antibodies (ANCA).Also provided herein are polynucleotides encoding the provided CAARs, genetically engineered cells such as T cells that contain the provided CAARs, and related methods and uses thereof in adoptive cell therapy.
Need to check novelty before this filing date? Find Prior Art